Choreo LLC Boosts Stock Position in Axon Enterprise, Inc (NASDAQ:AXON)

Choreo LLC lifted its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 35.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,836 shares of the biotechnology company's stock after purchasing an additional 745 shares during the quarter. Choreo LLC's holdings in Axon Enterprise were worth $1,492,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of AXON. Brighton Jones LLC acquired a new position in Axon Enterprise in the fourth quarter valued at about $480,000. Teacher Retirement System of Texas acquired a new position in Axon Enterprise in the fourth quarter valued at about $399,000. LPL Financial LLC lifted its position in Axon Enterprise by 13.5% in the fourth quarter. LPL Financial LLC now owns 101,431 shares of the biotechnology company's stock valued at $60,282,000 after buying an additional 12,052 shares during the last quarter. FineMark National Bank & Trust acquired a new stake in shares of Axon Enterprise during the fourth quarter worth about $255,000. Finally, TIAA Trust National Association lifted its position in shares of Axon Enterprise by 15.1% during the fourth quarter. TIAA Trust National Association now owns 1,457 shares of the biotechnology company's stock worth $866,000 after purchasing an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company's stock.

Axon Enterprise Stock Up 3.6%

Axon Enterprise stock traded up $25.75 during mid-day trading on Friday, hitting $735.01. The company had a trading volume of 654,601 shares, compared to its average volume of 627,317. The stock has a market cap of $57.22 billion, a price-to-earnings ratio of 177.54, a PEG ratio of 79.06 and a beta of 1.29. Axon Enterprise, Inc has a 1 year low of $279.02 and a 1 year high of $830.21. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The business has a fifty day moving average of $763.82 and a 200 day moving average of $650.42.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The business had revenue of $603.63 million for the quarter, compared to analyst estimates of $585.67 million. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The company's revenue for the quarter was up 31.3% compared to the same quarter last year. During the same period last year, the firm posted $1.15 earnings per share. On average, sell-side analysts expect that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, CRO Cameron Brooks sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The shares were sold at an average price of $740.76, for a total transaction of $2,222,280.00. Following the transaction, the executive directly owned 19,447 shares in the company, valued at approximately $14,405,559.72. This trade represents a 13.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Michael Garnreiter sold 5,913 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $760.00, for a total transaction of $4,493,880.00. Following the transaction, the director owned 17,740 shares in the company, valued at approximately $13,482,400. This trade represents a 25.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 34,642 shares of company stock valued at $25,090,528. 4.40% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on AXON shares. JPMorgan Chase & Co. increased their price target on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research report on Thursday, July 17th. Bank of America increased their price target on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $730.00 to $830.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Wolfe Research initiated coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They set an "outperform" rating on the stock. Finally, Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the stock an "overweight" rating in a research note on Friday, July 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Axon Enterprise presently has an average rating of "Moderate Buy" and a consensus target price of $772.08.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.